Close Menu

NEW YORK – PerkinElmer reported after the close of the market on Wednesday that its third quarter revenues jumped 36 percent year over year and beat the consensus Wall Street estimates for the top and bottom lines.

For the three months ended Sept. 30, the Waltham, Massachusetts-based firm posted revenues of $964.0 million compared to $706.9 million in the year-ago period. It beat analysts' average estimate of $841.2 million.

Organic revenue growth was 34 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.